Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Solution structure, aggregation behavior, and flexibility of human relaxin-2.

Haugaard-Kedström LM, Hossain MA, Daly NL, Bathgate RA, Rinderknecht E, Wade JD, Craik DJ, Rosengren KJ.

ACS Chem Biol. 2015 Mar 20;10(3):891-900. doi: 10.1021/cb500918v. Epub 2015 Jan 15.

PMID:
25547165
2.

The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution.

Eck MJ, Ultsch M, Rinderknecht E, de Vos AM, Sprang SR.

J Biol Chem. 1992 Feb 5;267(4):2119-22.

3.

X-ray structure of human relaxin at 1.5 A. Comparison to insulin and implications for receptor binding determinants.

Eigenbrot C, Randal M, Quan C, Burnier J, O'Connell L, Rinderknecht E, Kossiakoff AA.

J Mol Biol. 1991 Sep 5;221(1):15-21.

PMID:
1656049
4.

Self-association of human and porcine relaxin as assessed by analytical ultracentrifugation and circular dichroism.

Shire SJ, Holladay LA, Rinderknecht E.

Biochemistry. 1991 Aug 6;30(31):7703-11.

PMID:
1868050
5.

Use of recombinant DNA derived human relaxin to probe the structure of the native protein.

Canova-Davis E, Kessler TJ, Lee PJ, Fei DT, Griffin P, Stults JT, Wade JD, Rinderknecht E.

Biochemistry. 1991 Jun 18;30(24):6006-13.

PMID:
2043638
6.

Structural characterization by mass spectrometry of native and recombinant human relaxin.

Stults JT, Bourell JH, Canova-Davis E, Ling VT, Laramee GR, Winslow JW, Griffin PR, Rinderknecht E, Vandlen RL.

Biomed Environ Mass Spectrom. 1990 Nov;19(11):655-64.

PMID:
2076464
7.
8.
9.

Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.

Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA Jr.

J Immunol. 1985 Sep;135(3):2069-73.

PMID:
3926894
10.

The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin.

Lee SH, Aggarwal BB, Rinderknecht E, Assisi F, Chiu H.

J Immunol. 1984 Sep;133(3):1083-6.

PMID:
6430995
11.

Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.

Celada A, Gray PW, Rinderknecht E, Schreiber RD.

J Exp Med. 1984 Jul 1;160(1):55-74.

12.

Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation.

Rinderknecht E, O'Connor BH, Rodriguez H.

J Biol Chem. 1984 Jun 10;259(11):6790-7.

13.

Effects of bacteria-produced human alpha, beta, and gamma interferons on in vitro immune functions.

Shalaby MR, Weck PK, Rinderknecht E, Harkins RN, Frane JW, Ross MJ.

Cell Immunol. 1984 Apr 1;84(2):380-92.

PMID:
6231112
14.

Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin.

Stone-Wolff DS, Yip YK, Kelker HC, Le J, Henriksen-Destefano D, Rubin BY, Rinderknecht E, Aggarwal BB, Vilcek J.

J Exp Med. 1984 Mar 1;159(3):828-43.

15.

Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor.

Svedersky LP, Benton CV, Berger WH, Rinderknecht E, Harkins RN, Palladino MA.

J Exp Med. 1984 Mar 1;159(3):812-27.

16.

Importance of treatment regimen of interferon as an antitumor agent.

Lee SH, Chiu H, Rinderknecht E, Sabo W, Stebbing N.

Cancer Res. 1983 Sep;43(9):4172-5.

17.
18.
19.

Somatomedin-C shares the carboxy-terminal antigenic determinants with insulin-like growth factor-I.

Hintz RL, Rinderknecht E.

J Clin Endocrinol Metab. 1980 Sep;51(3):672-3.

PMID:
6157699
20.

Nonsuppressible insulin-like activity (NSILA) from human serum: recent accomplishments and their physiologic implications.

Zapf J, Rinderknecht E, Humbel RE, Froesch ER.

Metabolism. 1978 Dec;27(12):1803-28. Review. No abstract available.

PMID:
364249
21.

Primary structure of human insulin-like growth factor II.

Rinderknecht E, Humbel RE.

FEBS Lett. 1978 May 15;89(2):283-6. No abstract available.

22.
23.

Insulin-like growth factor: a model for tertiary structure accounting for immunoreactivity and receptor binding.

Blundell TL, Bedarkar S, Rinderknecht E, Humbel RE.

Proc Natl Acad Sci U S A. 1978 Jan;75(1):180-4.

Supplemental Content

Loading ...
Support Center